Cargando…

Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease

Patients with chronic kidney disease are often insulin resistant and glucose intolerant; abnormalities that promote cardiovascular disease. Administration of 1,25-dihydroxyvitamin D (calcitriol) has improved glucose metabolism in patients with end stage renal disease. We conducted a randomized, plac...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Boer, Ian H., Sachs, Michael, Hoofnagle, Andrew N., Utzschneider, Kristina M., Kahn, Steven E., Kestenbaum, Bryan, Himmelfarb, Jonathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509239/ https://www.ncbi.nlm.nih.gov/pubmed/22913981 http://dx.doi.org/10.1038/ki.2012.311

Ejemplares similares

Physical activity and metabolic health in chronic kidney disease: a cross-sectional study
por: Bowlby, Wilson, et al.
Publicado: (2016)

The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease
por: Bosworth, Cortney, et al.
Publicado: (2012)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease
por: Webb, Nicholas J. A., et al.
Publicado: (2017)

Assessment of kidney proximal tubular secretion in critical illness
por: Bhatraju, Pavan K., et al.
Publicado: (2021)

Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation
por: D’Marco, Luis, et al.
Publicado: (2022)

Does Secretory Clearance Follow Glomerular Filtration Rate in Chronic Kidney Diseases? Reconsidering the Intact Nephron Hypothesis
por: Chapron, A, et al.
Publicado: (2017)

Antiapoptotic Effect of Paricalcitol in Gentamicin-induced Kidney Injury
por: Suh, Sang Heon, et al.
Publicado: (2013)

Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
por: Ussif, Amin, et al.
Publicado: (2018)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
por: Cruzado, Josep M., et al.
Publicado: (2017)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3–4: a preliminary study
por: Hadjiyannakos, Dimitrios, et al.
Publicado: (2013)

Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease
por: Han, Tianzhao, et al.
Publicado: (2013)

Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Ponce, Daniela, et al.
Publicado: (2023)

Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial
por: Larsen, Thomas, et al.
Publicado: (2013)

Differential expression and regulation of Klotho by paricalcitol in the kidney, parathyroid and aorta of uremic rats
por: Ritter, Cynthia S., et al.
Publicado: (2015)

Paricalcitol Attenuates Contrast-Induced Acute Kidney Injury by Regulating Mitophagy and Senescence
por: Bae, Eunjin, et al.
Publicado: (2020)

Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial
por: Riccio, Eleonora, et al.
Publicado: (2015)

Potassium Measures and Their Associations with Glucose and Diabetes Risk: The Multi-Ethnic Study of Atherosclerosis (MESA)
por: Chatterjee, Ranee, et al.
Publicado: (2016)

Paricalcitol Improves Hypoxia-Induced and TGF-β1-Induced Injury in Kidney Pericytes
por: Lim, Jeong-Hoon, et al.
Publicado: (2021)

What's Next for Diabetes Prevention?
por: Kahn, Steven E., et al.
Publicado: (2011)

Variant APOL1 protein in plasma associates with larger particles in humans and mouse models of kidney injury
por: Andrews, Michael, et al.
Publicado: (2022)

Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Cardoso, Marilia Mastrocolla de Almeida, et al.
Publicado: (2022)

Paricalcitol Attenuates Metabolic Syndrome-Associated Heart Failure through Enhanced Mitochondrial Fusion
por: Nizami, Hina L., et al.
Publicado: (2022)

Effect of Early and Delayed Commencement of Paricalcitol in Combination with Enalapril on the Progression of Experimental Polycystic Kidney Disease
por: Sagar, Priyanka S., et al.
Publicado: (2021)

Randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease
por: Ahmadi, Armin, et al.
Publicado: (2023)

Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients
por: Izquierdo, María Jesús, et al.
Publicado: (2012)

Vitamin D Metabolites and Risk of Cardiovascular Disease in Chronic Kidney Disease: The CRIC Study
por: Hsu, Simon, et al.
Publicado: (2023)

Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis
por: Zhang, Zhuolin, et al.
Publicado: (2021)

Effects of paricalcitol combined with hemodiafiltration on bone-metabolism-related indexes in patients with diabetic nephropathy and chronic renal failure
por: Ma, Xiao-Ying, et al.
Publicado: (2023)

Biomarkers of Vitamin D Metabolism and Hip and Vertebral Fracture Risk: The Multi‐Ethnic Study of Atherosclerosis
por: Hsu, Simon, et al.
Publicado: (2022)

Protective Effects of Paricalcitol on Peritoneal Remodeling during Peritoneal Dialysis
por: Stavenuiter, Andrea W. D., et al.
Publicado: (2015)

Role of Paricalcitol in Modulating the Immune Response in Patients with Renal Disease
por: Lucisano, Silvia, et al.
Publicado: (2015)

Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics
por: Arenas Jimenez, María Dolores, et al.
Publicado: (2021)

Effects of Paricalcitol on Body Composition in Vitamin D-Deficient Rats
por: Koohpeyma, Farhad, et al.
Publicado: (2021)

Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
por: Chen, Xiu, et al.
Publicado: (2021)

Colesevelam Improves Oral but Not Intravenous Glucose Tolerance by a Mechanism Independent of Insulin Sensitivity and β-Cell Function
por: Marina, Anna L., et al.
Publicado: (2012)

Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport
por: Yeung, Catherine K., et al.
Publicado: (2013)

Vitamin D, parathyroid hormone, glucose metabolism and incident diabetes in the multiethnic study of atherosclerosis
por: Williams, Amaris, et al.
Publicado: (2022)

Long-Term Therapy Outcomes When Treating Chronic Kidney Disease Patients with Paricalcitol in German and Austrian Clinical Practice (TOP Study)
por: Obermüller, Nicholas, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_20g250jd4perk2bitfccnf2j5t